{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-139409","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.559675+00:00","generated_at":"2026-06-15T09:10:56.774350+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Viridian Therapeutics Q1 net loss $68.2M; VRDN-001 chronic TED data expected June/July 2023","bullets":["Net loss of $68.2M for Q1 2023 vs. $25.7M in Q1 2022; R&D expenses $50.7M including $15M upfront to Enable Injections.","Cash and short-term investments $373.9M at March 31, 2023, down from $424.6M at Dec 31, 2022; expected to fund into H2 2025.","Topline data from VRDN-001 proof-of-concept study in chronic TED expected June/July 2023; THRIVE-2 Phase 3 initiation planned mid-2023.","Lead subcutaneous (SC) program selection expected year-end 2023; IND for VRDN-003 to be filed Q2 2023.","Appointed Tony Casciano as CCO, Thomas Ciulla as CDO, and other senior executives during Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-139409","json":"https://secwatch.observer/filing/0001193125-23-139409.json","markdown":"https://secwatch.observer/filing/0001193125-23-139409.md","text":"https://secwatch.observer/filing/0001193125-23-139409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/0001193125-23-139409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/d473560d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:10:56.774350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6dbcdc48b3bd17dd0179c6e14a56e25bf084cddf","claim":"Viridian Therapeutics, Inc.\\DE reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/0001193125-23-139409-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}